[go: up one dir, main page]

FI946066L - Hepatiitti-C viruksen genotyyppien uudet sekvenssit ja niiden käyttö terapeuttisina ja diagnostisina aineina - Google Patents

Hepatiitti-C viruksen genotyyppien uudet sekvenssit ja niiden käyttö terapeuttisina ja diagnostisina aineina Download PDF

Info

Publication number
FI946066L
FI946066L FI946066A FI946066A FI946066L FI 946066 L FI946066 L FI 946066L FI 946066 A FI946066 A FI 946066A FI 946066 A FI946066 A FI 946066A FI 946066 L FI946066 L FI 946066L
Authority
FI
Finland
Prior art keywords
hepatitis
therapeutic
diagnostic agents
new sequences
virus genotypes
Prior art date
Application number
FI946066A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI946066A0 (fi
FI946066A7 (fi
Inventor
Geert Maertens
Lieven Stuyver
Original Assignee
Innogenetics Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innogenetics Nv filed Critical Innogenetics Nv
Publication of FI946066A0 publication Critical patent/FI946066A0/fi
Publication of FI946066A7 publication Critical patent/FI946066A7/fi
Publication of FI946066L publication Critical patent/FI946066L/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
FI946066A 1993-04-27 1994-04-27 Hepatiitti-C viruksen genotyyppien uudet sekvenssit ja niiden käyttö terapeuttisina ja diagnostisina aineina FI946066L (fi)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP93401099 1993-04-27
EP93402019 1993-08-05
PCT/EP1994/001323 WO1994025601A2 (en) 1993-04-27 1994-04-27 New sequences of hepatitis c virus genotypes and their use as therapeutic and diagnostic agents

Publications (3)

Publication Number Publication Date
FI946066A0 FI946066A0 (fi) 1994-12-23
FI946066A7 FI946066A7 (fi) 1994-12-23
FI946066L true FI946066L (fi) 1994-12-23

Family

ID=26134679

Family Applications (1)

Application Number Title Priority Date Filing Date
FI946066A FI946066L (fi) 1993-04-27 1994-04-27 Hepatiitti-C viruksen genotyyppien uudet sekvenssit ja niiden käyttö terapeuttisina ja diagnostisina aineina

Country Status (15)

Country Link
US (3) US6762024B2 (ja)
EP (4) EP0984068B1 (ja)
JP (5) JPH07508423A (ja)
CN (1) CN1108030A (ja)
AT (4) ATE551423T1 (ja)
AU (1) AU688323B2 (ja)
BR (1) BR9405334A (ja)
CA (2) CA2662090A1 (ja)
DE (1) DE69435023T2 (ja)
ES (1) ES2294779T3 (ja)
FI (1) FI946066L (ja)
NO (1) NO944967D0 (ja)
NZ (1) NZ266148A (ja)
SG (1) SG50563A1 (ja)
WO (1) WO1994025601A2 (ja)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE610436T1 (de) * 1991-11-21 1995-08-03 Common Services Agency Detektion des Hepatis-C Virus.
US6709828B1 (en) 1992-03-06 2004-03-23 N.V. Innogenetics S.A. Process for the determination of peptides corresponding to immunologically important epitopes and their use in a process for determination of antibodies or biotinylated peptides corresponding to immunologically important epitopes, a process for preparing them and compositions containing them
US6667387B1 (en) 1996-09-30 2003-12-23 N.V. Innogenetics S.A. HCV core peptides
US6380376B1 (en) * 1992-10-30 2002-04-30 Iowa State University Research Foundation Proteins encoded by polynucleic acids of porcine reproductive and respiratory syndrome virus (PRRSV)
US7258977B1 (en) * 1992-11-27 2007-08-21 Innogenetics N.V. Process for typing of HCV isolates
US7255997B1 (en) * 1993-04-27 2007-08-14 N.V. Innogenetics S.A. Sequences of hepatitis C virus genotypes and their use as therapeutic and diagnostic agents
WO1994025601A2 (en) 1993-04-27 1994-11-10 N.V. Innogenetics S.A. New sequences of hepatitis c virus genotypes and their use as therapeutic and diagnostic agents
ATE281526T1 (de) 1993-05-05 2004-11-15 Common Services Agency Hepatitis-c virus typ 4,5 und 6
US7070790B1 (en) 1993-06-29 2006-07-04 The United States Of America As Represented By The Department Of Health And Human Services Nucleotide and deduced amino acid sequences of the envelope 1 and core genes of isolates of hepatitis C virus and the use of reagents derived from these sequences in diagnostic methods and vaccines
US5882852A (en) * 1993-06-29 1999-03-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Hepatitic C virus (HCV) core gene nucleotide sequences and related methods of detecting major and minor genotypes of HCV isolates
US5514539A (en) * 1993-06-29 1996-05-07 The United States Of America As Represented By The Department Of Health And Human Services Nucleotide and deduced amino acid sequences of the envelope 1 gene of 51 isolates of hepatitis C virus and the use of reagents derived from these sequences in diagnostic methods and vaccines
CA2201703A1 (en) 1994-10-21 1996-05-09 Geert Maertens New sequences of hepatitis c virus genotypes and their use as prophylactic, therapeutic and diagnostic agents
US5851759A (en) * 1996-04-19 1998-12-22 Chiron Corporation Heteroduplex tracking assay (HTA) for genotyping HCV
EP2298900A1 (en) * 1996-09-17 2011-03-23 Novartis Vaccines and Diagnostics, Inc. Compositions and methods for treating intracellular diseases
TR200202213T2 (tr) 1998-04-17 2002-11-21 Innogenetics N.V. İndirgeme ajanlarını kullanarak geliştirilen immünodiagnostik tahliller
AU4497999A (en) * 1998-04-28 1999-11-16 Ingrid-Corina Bergter Radioimmunopharmaca for treating hepatitis c
EP1113777B1 (en) * 1998-06-09 2007-01-10 Andrea D. Branch Novel hepatitis c virus peptides and uses thereof
US7052830B1 (en) 1998-06-09 2006-05-30 Branch Andrea D Hepatitis C virus peptides and uses thereof
AU2001272948A1 (en) * 2000-06-15 2001-12-24 Chiron Corporation Hcv antigen/antibody combination assay
US6680059B2 (en) * 2000-08-29 2004-01-20 Tripep Ab Vaccines containing ribavirin and methods of use thereof
JP5175417B2 (ja) * 2000-08-17 2013-04-03 トリペップ アクチ ボラゲット リバビリンを含むワクチンおよびその使用方法
US6858590B2 (en) * 2000-08-17 2005-02-22 Tripep Ab Vaccines containing ribavirin and methods of use thereof
US7022830B2 (en) * 2000-08-17 2006-04-04 Tripep Ab Hepatitis C virus codon optimized non-structural NS3/4A fusion gene
US7196183B2 (en) * 2001-08-31 2007-03-27 Innogenetics N.V. Hepatitis C virus genotype, and its use as prophylactic, therapeutic and diagnostic agent
MD2149G2 (ro) * 2001-11-23 2003-10-31 Институт Генетики И Физиологии Растений Академии Наук Молдовы Primer oligonucleotidic pentru depistarea ARN-ului virusului hepatitei C
DK2014671T3 (da) * 2002-03-11 2010-09-20 Lab 21 Ltd Fremgangsmåder og sammensætninger til identificering og karakterisering af hepatitis C
CA2484941A1 (en) 2002-07-24 2004-02-05 Intercell Ag Antigens encoded by alternative reading frame from pathogenic viruses
EP1537418A2 (en) 2002-09-13 2005-06-08 Intercell AG Method for isolating hepatitis c virus peptides
EP2345420B1 (en) 2003-03-24 2016-01-06 Valneva Austria GmbH Use of a TH1 immune response inducing adjuvant for enhancing immune responses
EP2275131A3 (en) 2003-07-11 2012-01-25 Intercell AG HCV Vaccines
US8124747B2 (en) 2003-08-29 2012-02-28 Innogenetics HCV clade and prototype sequences thereof
WO2005067643A2 (en) 2004-01-07 2005-07-28 Third Wave Technologies, Inc. Determination of hepatitis c virus genotype
US20060162667A1 (en) * 2005-01-26 2006-07-27 Papadoyianis Ernest D Aquatic habitat and ecological tank
CA2618429A1 (en) * 2005-05-25 2007-03-22 Tripep Ab A hepatitis c virus non-structural ns3/4a fusion gene
US20070072211A1 (en) 2005-06-30 2007-03-29 Roche Molecular Systems, Inc. Asymmetric PCR coupled with post-PCR characterization for the identification of nucleic acids
MD3300G2 (ro) * 2006-09-28 2007-11-30 Институт Генетики, Физиологии И Защиты Растений Академии Наук Молдовы Primer oligonucleotidic pentru depistarea ARN-ului virusului hepatitei C
EP2527474A1 (en) 2006-10-20 2012-11-28 Innogenetics N.V. Methodology for analysis of sequence variations within the HCV NS3/4A genomic region
US20090325145A1 (en) 2006-10-20 2009-12-31 Erwin Sablon Methodology for analysis of sequence variations within the hcv ns5b genomic region
EP2121990A2 (en) * 2006-10-20 2009-11-25 Innogenetics N.V. Methodology for anaysis of sequence variations within the hcv ns5b genomic region
EA018102B1 (ru) * 2007-08-09 2013-05-30 Федеральное Государственное Бюджетное Учреждение Науки Институт Молекулярной Биологии Им. В.А. Энгельгардта Российской Академии Наук (Имб Ран) Способ идентификации генотипа и подтипа вируса гепатита c на биологическом микрочипе
WO2009022236A2 (en) 2007-08-16 2009-02-19 Tripep Ab Immunogen platform
US20090220943A1 (en) * 2007-10-30 2009-09-03 Intermune, Inc. Hcv genotyping and phenotyping
WO2009130588A2 (en) * 2008-04-22 2009-10-29 Tripep Ab Immunogen platform
WO2010112733A1 (fr) * 2009-03-30 2010-10-07 bioMérieux Support solide de détection du vhc
WO2013150450A1 (en) * 2012-04-02 2013-10-10 Universidade Do Porto Hcv homolog fragments, cell-lines and applications thereof
DK3274478T3 (da) * 2015-03-27 2020-11-23 Ortho Clinical Diagnostics K K Hcv-ns4a/modificerede ns3-polypeptider og anvendelser deraf
EP3494227B1 (en) * 2016-08-02 2024-12-11 Roche Diagnostics GmbH Helper oligonucleotide for improving efficiency of amplification and detection/quantitation of nucleic acids

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3886363T3 (de) * 1987-11-18 2004-09-09 Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville NANBV-Diagnostika
US5350671A (en) 1987-11-18 1994-09-27 Chiron Corporation HCV immunoassays employing C domain antigens
GB2236819B (en) * 1989-09-14 1993-07-14 Gen Motors France Dual master cylinder
CA2065287C (en) * 1989-09-15 1999-12-21 Tatsuo Miyamura New hcv isolates
US5372928A (en) * 1989-09-15 1994-12-13 Chiron Corporation Hepatitis C virus isolates
AU642942B2 (en) 1989-12-18 1993-11-04 Wellcome Foundation Limited, The Viral agent
EP0435229A1 (en) * 1989-12-27 1991-07-03 Sanwa Kagaku Kenkyusho Co., Ltd. DNA of non-A, non-B hepatitis virus gene, its clone and use thereof
WO1991014779A1 (fr) * 1990-03-28 1991-10-03 Mitsui Toatsu Chemicals, Incorporated Diagnostic du virus de l'hepatite
EP0461863A1 (en) * 1990-06-12 1991-12-18 Immuno Japan Inc. Oligonucleotide primers, and their application for high-fidelity detection of non-A, non-B hepatitis virus
NZ238681A (en) 1990-06-25 1992-03-26 Univ Osaka Res Found Non-a, non-b hepatitis virus particles and their production
ATE185350T1 (de) 1990-12-14 1999-10-15 Innogenetics Nv Synthetische antigene zum nachweis von antikörpern gegen hepatitis c virus
EP0510952A1 (en) * 1991-04-26 1992-10-28 Immuno Japan Inc. Oligonucleotide primers and their application for high-fidelity detection of non-a, non-b hepatitis virus
RO117267B1 (ro) * 1991-05-08 2001-12-28 Chiron Corp Secventa de acid nucleic si peptida codificata de aceasta, pentru diagnostic si tratament
EP0591431B1 (en) 1991-06-24 2002-12-11 Chiron Corporation Hepatitis c virus (hcv) polypeptides
EP0532167A3 (en) * 1991-08-09 1993-03-31 Immuno Japan Inc. Non-a, non-b hepatitis virus genome, polynucleotides, polypeptides, antigen, antibody and detection systems
AU2513592A (en) * 1991-08-21 1993-03-16 Abbott Laboratories Hepatitis c assay utilizing recombinant antigens to ns1
ES2182822T3 (es) 1991-09-13 2003-03-16 Chiron Corp Composiciones de polipeptidos inmunorreactivos del virus de la hepatitis c.
DE610436T1 (de) * 1991-11-21 1995-08-03 Common Services Agency Detektion des Hepatis-C Virus.
DE69324678T2 (de) * 1992-11-27 1999-12-09 Naamloze Vennootschap Innogenetics S.A., Gent Verfahren zur typisierung von hcv-isolaten
WO1994025601A2 (en) 1993-04-27 1994-11-10 N.V. Innogenetics S.A. New sequences of hepatitis c virus genotypes and their use as therapeutic and diagnostic agents
EP0698216B2 (en) 1993-05-10 2009-02-25 Novartis Vaccines and Diagnostics, Inc. Methods of typing hepatitis c virus and reagents for use therein
JPH06319563A (ja) 1993-05-13 1994-11-22 Imuno Japan:Kk Ｃ型肝炎ウイルス遺伝子、オリゴヌクレオチド、並びにｃ型 肝炎ウイルス遺伝子型判定方法
US5882852A (en) 1993-06-29 1999-03-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Hepatitic C virus (HCV) core gene nucleotide sequences and related methods of detecting major and minor genotypes of HCV isolates
US5514539A (en) * 1993-06-29 1996-05-07 The United States Of America As Represented By The Department Of Health And Human Services Nucleotide and deduced amino acid sequences of the envelope 1 gene of 51 isolates of hepatitis C virus and the use of reagents derived from these sequences in diagnostic methods and vaccines
JP2687852B2 (ja) * 1993-10-13 1997-12-08 日本電気株式会社 半導体メモリ装置

Also Published As

Publication number Publication date
US20030032005A1 (en) 2003-02-13
US6762024B2 (en) 2004-07-13
EP1004670A2 (en) 2000-05-31
NO944967L (no) 1994-12-21
JP2004041206A (ja) 2004-02-12
DE69435023T2 (de) 2008-09-11
AU688323B2 (en) 1998-03-12
EP0984067B1 (en) 2012-04-04
US7157226B1 (en) 2007-01-02
CN1108030A (zh) 1995-09-06
EP0984067A3 (en) 2000-09-27
NO944967D0 (no) 1994-12-21
EP0984068A2 (en) 2000-03-08
EP0984067A2 (en) 2000-03-08
JP2004041207A (ja) 2004-02-12
CA2139100C (en) 2009-06-23
EP0984068A3 (en) 2000-09-20
WO1994025601A3 (en) 1995-03-02
JPH07508423A (ja) 1995-09-21
NZ266148A (en) 1997-06-24
JP2002233388A (ja) 2002-08-20
EP0984068B1 (en) 2012-03-28
EP0651807B1 (en) 2007-09-12
DE69435023D1 (de) 2007-10-25
WO1994025601A2 (en) 1994-11-10
BR9405334A (pt) 1999-05-25
EP0651807A1 (en) 1995-05-10
EP1004670B1 (en) 2012-04-11
US20030008274A1 (en) 2003-01-09
ATE552340T1 (de) 2012-04-15
ATE553201T1 (de) 2012-04-15
AU6722294A (en) 1994-11-21
CA2139100A1 (en) 1994-11-10
FI946066A0 (fi) 1994-12-23
ATE551423T1 (de) 2012-04-15
US7195765B2 (en) 2007-03-27
EP1004670A3 (en) 2000-09-20
JP2002233389A (ja) 2002-08-20
ATE373093T1 (de) 2007-09-15
ES2294779T3 (es) 2008-04-01
SG50563A1 (en) 1998-07-20
FI946066A7 (fi) 1994-12-23
CA2662090A1 (en) 1994-11-10

Similar Documents

Publication Publication Date Title
FI946066L (fi) Hepatiitti-C viruksen genotyyppien uudet sekvenssit ja niiden käyttö terapeuttisina ja diagnostisina aineina
DK1136075T3 (da) Kombinationsterapi til udryddelse aff detekterbart HCV-RNA i patienter med kronisk hepatitis C infektion
FI20080432L (fi) L-nukleosidejä hepatiitti-B-viruksen ja Epstein-Barr-viruksen hoitamiseksi
ITMI931522A1 (it) Composizione farmaceutiche per il trattamento dell'infezione da virus dell'epatite b (hbv)
FI942634A7 (fi) Lääkeruiskut ja menetelmät
BR9206131A (pt) Hepatite C: diagnóstico e vacinas
ZA956276B (en) Insect viruses sequences insecticidal compositions and methods of use
EE9900036A (et) Uued ühendid ja kompositsioonid trüptaasi aktiivsusega seotud haiguste raviks
FI925261A7 (fi) Virushepatiitin diagnoosi ja hoito
NO941983D0 (no) Engangs-spröyte
DE69433215D1 (de) Medizinische Spritze
NO955258D0 (no) Medisinsk anvendelse av enzymer
EE9400068A (et) Ravimsegud viirushepatiidi B (HBV) infektsiooni ja selle poolt p6hjustatud haiguste raviks ja nende valmistamise protsess
FI924475A7 (fi) Trinitrobentseenien tai karmiinihapon käyttö syövän ja virusperäisten sairauksien hoidossa
FI954138L (fi) Hydroksimetyylifuratsaanikarboksyylihappojohdannaiset ja niiden käyttö sydänverisuonitautien käsittelyssä
EP1068362A4 (en) HEPATITIS C VIRUS NS5B COMPOSITIONS AND METHOD FOR THEIR USE
ZA964094B (en) Compositions and methods for the diagnosis of and vaccination against hepatitis c virus (hcv)
GB9701919D0 (en) Materials and methods relating to the diagnosis of susceptibility to HIV-1 infection and to treatment methods related to HIV-1
ITMI922534A1 (it) Uso di acidi aril-, eteroaril- e alchiltartronici come agenti terapeutici
BR7401733U (pt) Seringa travável descartável
GB9621866D0 (en) Materials and methods relating to the diagnosis and prophylactic and therapeutic treatment of hepatitis B virus infection and leprosy
MXPA94003453A (es) Metodo y composicion para el tratamiento de pacientes con hepatitis b que tienen descompensacion hepatica.
BR7300880U (pt) Disposição em seringa dental descartável
LTIP472A (en) Composition for the treatment of infection and disease caused by hepatit b virus
BR9401688A (pt) Seringa hipodérmica não reutilizável